CAFs can enhance the expression of PD‐L1 on tumor cells, which subsequently binds to PD‐1 on activated T cells, thereby inhibiting T cell activation signals and limiting the function of cytotoxic T cells, ultimately blocking antitumor immunity. The gene discussed is CD274; the disease is neoplasm.